相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Bone mineral density and risk of breast cancer in postmenopausal women
Xinhua Qu et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Fracture Risk in Older, Long-Term Survivors of Early-Stage Breast Cancer
Pamala A. Pawloski et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2013)
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
F. Nuzzo et al.
ANNALS OF ONCOLOGY (2012)
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
Jennifer A. Ligibel et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy
William Jacot et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
Angela M. Cheung et al.
LANCET ONCOLOGY (2012)
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Risk Factors for Breast Cancer and Expression of Insulin-Like Growth Factor-2 (IGF-2) in Women with Breast Cancer in Wuhan City, China
Jun Qiu et al.
PLOS ONE (2012)
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
P. Hadji et al.
ANNALS OF ONCOLOGY (2011)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
Meredith M. Regan et al.
LANCET ONCOLOGY (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women
Silvano Adami et al.
BONE (2010)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Reproductive correlates of bone mass in elderly women
Kathleen M. Fox et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Perspective how many women have osteoporosis?
L. Joseph Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
Timothy J. Key et al.
LANCET ONCOLOGY (2010)
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
Christos Markopoulos et al.
BREAST CANCER RESEARCH (2010)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M. Rabaglio et al.
ANNALS OF ONCOLOGY (2009)
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Marc J. Gunter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
James E. Lester et al.
CLINICAL CANCER RESEARCH (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
Adam Brufsky et al.
ONCOLOGIST (2008)
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients
Yukie Yonehara et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2007)
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
C. B. Confavreux et al.
BONE (2007)
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis
Benjamin M. P. Tang et al.
LANCET (2007)
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
Paul E. Goss et al.
BREAST CANCER RESEARCH (2007)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
PE Goss et al.
BONE (2004)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Long-term risk of osteoporotic fracture in Malmo
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
